Drug Combo Proves Powerful Against Lung Cancer New Rochelle NY

A two-drug combination treatment in New Rochelle proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Herbert Gretz
(212) 427-9898
525 E 68Th St
New York, NY
Michael Schuster
(212) 746-2119
525 East 68th Street
New York, NY
Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
Steven Edward Vogl
(718) 519-7774
2220 Tiemann Ave
Bronx, NY
Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
Kee Y Shum MD
(212) 941-0660
254 Canal St
New York, NY
Ron Bakal
(212) 679-6464
461 Park Avenue South
New York, NY
Richard G Stock MD
(212) 241-7502
1184 5th Ave
New York, NY
Norman Lester Rosen
(914) 965-2060
3333 Henry Hudson Way
Bronx, NY
meena Ahluwalia
(718) 250-6960
121 dekalb Ave
brooklyn, NY
Data Provided by:
  

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Lung Cancer New Rochelle NY
Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.
- Genetic Clues for Skin Cancer Therapies New Rochelle NY
- Hormone Therapy for Breast Cancer New Rochelle NY
- Fungal Infection Treatments New Rochelle NY
- Exercise for Breast Cancer Survival New Rochelle NY
- Risks for Childhood Cancer Survivors New Rochelle NY
- Side Effect Of Chemotherapy Drugs New Rochelle NY
- Delayed Prostate Cancer Therapy New Rochelle NY
- Exercise for Prostate Cancer New Rochelle NY